<DOC>
	<DOCNO>NCT02251938</DOCNO>
	<brief_summary>The objective extension study evaluate long-term safety treatment DE-109 ( 440 μg ) subject non-infectious uveitis posterior segment eye participate SAKURA development program .</brief_summary>
	<brief_title>A Phase IIIb , Multinational , Multicenter , Open-Label Extension Study Assessing Long-Term Safety PRN Intravitreal Injections DE-109 Subjects With Non-Infectious Uveitis Posterior Segment Eye Who Have Participated SAKURA Development Program</brief_title>
	<detailed_description>This multicenter , open-label , extension study intravitreal injection 440 μg dose DE-109 subject non-infectious uveitis posterior segment receive dose DE-109 exit SAKURA program Santen Protocol 32-007 , Amendment 05 . Subjects randomize receive least two injection DE-109 first five month SAKURA program obtain clinical benefit study medication , determine Investigator , may consider entry 12-month extension study . The minimum time lag last injection SAKURA program entry current protocol 60 day .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Participated SAKURA study 2 . Received clinical benefit treatment SAKURA study 3 . Ability sign inform consent attend study visit 1 . Uveitis infectious etiology 2 . Implanted device 3 . Suspected confirmed central nervous system ocular lymphoma 4 . Uncontrolled glaucoma 5 . Significant ocular disease 6 . Intravitreal injection past 60 day 7 . Intraocular surgery treatment 8 . Ocular periocular infection 9 . History herpetic infection 10 . Toxoplasmosis toxoplasmosis scar 11 . Ocular malignancy 12 . Vitrectomy 13 . Allergy hypersensitivity study drug 14 . Participation uveitis device clinical trial within 30 day 15 . Any recent systemic condition/infection 16 . Immunosuppressive therapy immunocomprimised 17 . Cytomegalovirus infection 18 . Malignancy remission 19 . Females pregnant lactate use adequate contraceptive 20 . Medical marijuana illegal drug use 21 . Systemic saroidosis 22 . Therapeutic radiation head neck</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>